Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers

被引:0
|
作者
Wojciech Krzyzanski
Elzbieta Wyska
机构
[1] University at Buffalo,Department of Pharmaceutical Sciences
[2] State University of New York,Department of Pharmacokinetics and Physical Pharmacy
[3] Jagiellonian University,undefined
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2008年 / 377卷
关键词
Target-mediated drug disposition; Pharmacokinetic model; Receptor binding; Internalization;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug–receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel = 0.106 h−1 and Vc = 0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33–99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.
引用
收藏
页码:637 / 645
页数:8
相关论文
共 50 条
  • [41] INFLUENCE OF MELOXICAM ON FUROSEMIDE PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY-VOLUNTEERS
    MULLER, FO
    SCHALL, R
    DEVAAL, AC
    GROENEWOUD, G
    HUNDT, HKL
    MIDDLE, MV
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 48 (3-4) : 247 - 251
  • [42] Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion
    Ericsson, H
    Fakt, C
    Höglund, L
    Jolin-Mellgård, Å
    Nordlander, M
    Sunzel, M
    Regårdh, CG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) : 61 - 67
  • [43] The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers
    Liu, Guojing
    Wen, Jiagen
    Guo, Dong
    Wang, Zhenmin
    Hu, Xiaolei
    Tang, Jie
    Liu, Zhaoqian
    Zhou, Honghao
    Zhang, Wei
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 132 (04) : 244 - 248
  • [44] Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
    Peterschmitt, M. Judith
    Crawford, Nigel P. S.
    Gaemers, Sebastiaan J. M.
    Ji, Allena J.
    Sharma, Jyoti
    Pham, Theresa T.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (01): : 86 - 98
  • [45] Pharmacokinetics and pharmacodynamics of dexmedetomidine-induced vasoconstriction in healthy volunteers
    Talke, Pekka
    Anderson, Brian J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (06) : 1364 - 1372
  • [46] Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion
    H. Ericsson
    C. Fakt
    L. Höglund
    Å. Jolin-Mellgård
    M. Nordlander
    M. Sunzel
    C. G. Regårdh
    European Journal of Clinical Pharmacology, 1999, 55 : 61 - 67
  • [47] Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers
    Min, DI
    Ku, YM
    Geraets, DR
    Lee, HC
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (05): : 469 - 476
  • [48] Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety
    Saiz-Rodriguez, Miriam
    Belmonte, Carmen
    Derqui-Fernandez, Nieves
    Cabaleiro, Teresa
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Ovejero-Benito, Maria C.
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (16) : 1491 - 1502
  • [49] The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers
    Faaij, RA
    van Griensven, JMT
    Schoemaker, RC
    Goggin, T
    Guenzi, A
    Kroon, JM
    Burggraaf, J
    Cohen, AF
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) : 25 - 29
  • [50] PHARMACOKINETICS AND PHARMACODYNAMICS OF TUCARESOL, AN ANTISICKLING AGENT, IN HEALTHY-VOLUNTEERS
    ROLAN, PE
    MERCER, AJ
    WOOTTON, R
    POSNER, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) : 375 - 380